| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2021: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
G47Δ is an oncolytic virus that can replicate selectively in and destroys only cancer cells, and provides high efficacy and effective antitumor immunity induction as well as high safety. In 2021, G47Δ was approved as a new drug for malignant glioma in Japan. G47Δ is effective against various types of cancer, and an expansion of applications is intended for cancer that is refractory to current standard therapies.
G47Δ exhibits specific antitumor immunity in the course of replication in cancer cells, and thus ast as an in situ cancer vaccine. In this study, we generated viruses that further enhances antitumor immunity using G47Δ as a backbone, and confirmed the enhancement of the therapeutic effect of newly constructed viruses.
|
